• Camp4 Therapeutics director Andrew J. Schwab reported a sale of 400,000 common shares on Aug. 27.
• Shares sold at USD 4.04, held indirectly through 5AM Ventures VI.
• 5AM Ventures VI stake fell to 2,033,270 shares following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Camp4 Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001598549-26-000011), on August 31, 2026, and is solely responsible for the information contained therein.